Racial Disparities In Outpatient Medical Management Of Patients With Heart Failure With Reduced Ejection Fraction
Njemeh Danso,Alaa M. Omar,Juan Arango Morales,Darren Kong,Won-Joon Koh,Swiri Konje,Arpanjeet kaur,Cathleen Varley,Sean Pinney,Ashish Correa,Johannita Contreras,Arieh Fox,Kiran Mahmood,Lady Njemeh Danso
DOI: https://doi.org/10.1016/j.cardfail.2023.10.447
IF: 6.592
2024-01-01
Journal of Cardiac Failure
Abstract:Introduction Environmental, socioeconomic and medical risk factors’ among patients with heart failure (HF) with reduced ejection fraction (HFrEF) may cause clinical and prognostic differences. We studied the racial and ethnic prognostic implications of HFrEF medical management among outpatients treated in our inner-city practice. Methods In a retrospective protocol, we studied patients referred to the HF clinic at our institution from October 2020 to October 2021. Clinical, hemodynamic, echocardiographic, socio-economic data and the use of guideline-directed medical therapy (GDMT) were collected. Patients were followed for a median of 16.7 months for HF hospitalizations, mortality as well as their composite. Results In the study period, 506 patients were included (67.4±14 years, 46% women, LVEF: 32.9±13%). 69(13%) patients were of white race, 99(20%) were Hispanics, 267(53%) were African Americans (AA), and 71(14%) patients were of other races. During follow-up, 155(31%) patients had HF admissions, 60(12%) died and 180(36%) had the combined outcomes. Figure 1A shows basic differences stratified by race. Regarding GDMT, AA and Hispanic patients showed the least use of individual GDMT and the least use of the full set of GDMT. Importantly, AA and Hispanics had more medication non-adherence, while AA showed the most clinic visits no shows. Interestingly, apart from more chronic kidney disease (CKD) in AA and Hispanics, other common medication side effects such as hypotension, bradycardia, hyperkalemia were not different between races. Importantly, more deaths, HF hospitalization, and combined outcomes (Figure 1 A to D) occurred in Hispanics and AA compared to other groups (Figure 1A). Survival analyses for the risk of combined outcomes showed that whites did not have different risks (HR: 1.7, 95% CI: 0.79 to 3.7, Figure), while Hispanics (HR: 2.1, 95% CI: 1.1 to 4.3) and AA (HR: 3.7, 95% CI: 2 to 6.9) had higher risk compared to other races. After adjusting for covariates (age, sex, individual GDMT, CRT, CKD, GFR, EF, medication non-adherence, and clinic no-shows), only AA continued to have elevated risk for combined outcomes (HR: 2.9, 95% CI: 1.5 to 5.6), while whites and Hispanics lost statistical significance. Conclusions Racial and ethnic disparities had prognostic significance in the outpatient management of HFrEF in terms of worse hospitalizations and mortality in the Hispanic and AA populations. Such findings may be attributed to patient factors (less medication and clinic visits non-adherance), and physician factors (stopping medications due to renal dysfunction). AA had worse outcomes even after adjusting for covariates suggesting further studies are needed to determine a more effective therapeutic approach in this population.
cardiac & cardiovascular systems